Pivotal Therapeutics Inc (PVTTF: OTCQX International) |

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Pivotal Therapeutics Inc (PVTTF: OTCQX International) | Pivotal Therapeutics Announces 2013 Financial Results Pivotal Therapeutics Announces 2013 Financial Results

Pivotal Therapeutics Announces 2013 Financial Results

Canada NewsWire

WOODBRIDGE, ON , April 30, 2014 /CNW/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced its operational highlights and financial results for the fiscal year ended December 31, 2013 . All dollar amounts referenced herein are in Canadian dollars unless otherwise stated.

Financial Review

Sales for the year ended 2013 totaled $303,530 versus $93,637 in 2012. The increase in sales is attributed to greater understanding, by healthcare practitioners, of an Omega-3 deficiency (OM3D) as an underlying risk factor of cardiovascular disease and how VASCAZEN ® 's unique formulation can correct that deficiency.

"With the completion of the recent financing the Company is now in a position to execute on its commercialization plans for both VASCAZEN ® and OMAZEN ® ," said Mr. Eugene Bortoluzzi , Chief Executive Officer and Chief Financial Officer. "We look forward to 2014 and the opportunity to further business development initiatives and bring to fruition research and development efforts."

For the twelve months ended December 31, 2013 the Company reported a loss of $3.0 million , or $0.04 per common share, compared with a loss of $3.6 million , or $0.05 per common share for the twelve months ended December 31, 2012 . The decrease in loss of $745,342 is attributed to the improvement in revenues combined with a reduction in operating expenses.

The audited consolidated financial statements, accompanying notes thereto and Management's Discussion and Analysis for the year ended December 31, 2013 , will be accessible on SEDAR www.sedar.com , CSE www.cnsx.ca under the symbol "PVO" and OTCQX www.otcqx.com under the symbol "PVTTF".

Highlights from 2013:

  • March 6, 2013 - The Company exhibited at the American College of Cardiology's 62 nd annual scientific session and EXPO;

  • April 9, 2013 - VASCAZEN ® -REVEAL trial top-line results accepted for presentation at the American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) 2013 Scientific Sessions;

  • April 30, 2013 - the Company presented top-line results from its recently concluded VASCAZEN ® -REVEAL clinical trial in a poster presentation entitled "Treatment of Omega-3 Nutritional Deficiency Improves Cardiovascular Disease Risk Factors: Results of the Randomized, Double-Blind, Placebo-Controlled VASCAZEN ® -REVEAL Trial" at the American Heart Association's ATVB 2013 Scientific Sessions;

  • May 2, 2013 - Dr. George Jackowski , the Company's co-founder and Chairman, was awarded the Queen Elizabeth II Diamond Jubilee Medal for his significant contribution to the Canadian Biotech and Pharmaceutical Industries;

  • May 7, 2013 - the Company presented positive, statistically significant, top-line results from its VASCAZEN ® -REVEAL trial announcing that it met primary and secondary endpoints and showed a 121% correction of an Omega-3 deficiency after only eight weeks of treatment;

  • October 2, 2013 - the Company announced the closing of the equity portion of the financing for $2,741,809 and the continuation of financing efforts by way of Convertible Promissory Notes for up to an additional $5,000,000 ;

  • October 7, 2013 - the Company received $1,649,280 under the debt financing;

  • November 1, 2013 - the Company announced the extension of the debt financing.

Highlights Subsequent to Year-end:

  • January 29, 2014 - The Company announced a Notice of Allowance for the patent entitled "Formulations Comprising Omega-3 Fatty Acids and Anti-Obesity Agent for the Reduction of Body Weight in Cardiovascular Disease Patients (CVD) and Diabetics"

  • March 4, 2014 - The Company closed the debt financing and receives over CDN $7.7 million to further Vascazen ® commercialization;

  • March 14, 2014 and April 8, 2014 - The Company awarded stock options that were granted previously to certain of its directors, officers, employees and consultants in recognition of their contributions made in 2012 and 2013 and were awaiting the conclusion of the financing.


 Pivotalʼs Goals for 2014:

  • Drive top-line revenues;

  • Develop a point-of-care diagnostic test to measure Omega-3 deficiency (OM3D);

  • Advance commercialization of Vascazen ® in the U.S. and internationally;

  • Advance commercialization of OMAZEN ® in Canada ;

  • Expansion of the sales & marketing initiatives;

  • Initiation of new clinical trials;

  • Publication of scientific data;

  • Expansion of intellectual property portfolio;

  • Investigation of international licensing opportunities;

  • Expansion of product offerings;

  • Investment community presentations to increase awareness;

  • Presentations and attendance at scientific meetings.

About Pivotal Therapeutics Inc.

Pivotal Therapeutics is a publicly traded (OTCQX: PVTTF) (CSE: PVO) specialty pharmaceutical company with a focus on cardiovascular disease and overall health. Pivotal Therapeutics' lead product VASCAZEN ® is a prescription only Medical Food formulated to meet the dietary Omega-3 deficient needs of patients with cardiovascular disease through elevating Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) to levels associated with reduced risk of cardiovascular complications. OMAZEN ® is a pharmaceutical grade Omega-3 providing over 90% pure Omega-3 in each capsule for the maintenance of good health. OMAZEN ® is a patented product available for sale and distribution in Canada .

About VASCAZEN ®

VASCAZEN ® is currently available in the U.S. as a prescription only Medical Food specifically formulated for the dietary management of an Omega-3 deficiency in cardiovascular patients. VASCAZEN ® is a > 90% pure Omega-3 with a proprietary 6:1 EPA:DHA fatty acid formulation, protected by a series of both U.S. and foreign patents.

VASCAZEN ® has been clinically shown to correct an Omega-3 deficiency within eight weeks of treatment with positive concomitant effects on the lipid profiles, mainly a 48% reduction of triglycerides and an increase of HDL without negative impact on the LDL-C lipid profile.   VASCAZEN ® 's results were achieved with a dose of 3 grams of EPA and DHA per day of a prescription grade, high purity Omega-3.

Disclosure Notice

The information contained in this document is as of April 30, 2014 . This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause Pivotal's actual results to differ materially from those projected in such forward-looking statements. These statements can be identified by the use of words such as "will", "anticipate", "estimate", "expect", "project", "forecast", "intend", "plan", "believe", "project", "potential", and similar expressions with any discussion of future operating or financial performance or events. In particular, factors that could cause actual results to differ materially from those in forward looking statements include the following: Pivotal's inability to obtain additional financing on acceptable terms; growth in costs and expenses; inability to compete with others who provide comparable products; risk that the Company's products will not gain widespread market acceptance; risks relating to the Company's ability to maintain its CSNX listing. Forward-looking statements speak only as of the date made and are not guarantees of future performance. The Company undertakes no obligation to publicly update or revise any forward-looking statements contained in this document as a result of new information or future events or developments. CNSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this information.

SOURCE Pivotal Therapeutics Inc.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Art Limitless Jury Puts SDG 12 and Art Into Clear Focus

Updated Category News Views 56

A paint pigment, a discarded object, and a serious climate question have landed in the same room. BE OPEN Art’s 2026 Art Limitless competition is aimed at SDG 12, the United Nations goal centered on responsible production and consumption. That may sound like institutional language built for conference folders, but the underlying issue is plain enough: society cannot...

Continue Reading
NetEase Miss Opens an Investigation, Not a Verdict

Updated Category News Views 132

A two-dollar earnings gap can make a shareholder base jumpy fast, and NetEase just handed the market a rough set of numbers to chew on. The November 19 notice says NetEase's third-quarter 2026 report missed Wall Street expectations on both earnings and revenue, followed by a sharp decline in the shares. That has prompted SueWallSt, powered by Levi & Korsinsky LLP, to...

Continue Reading
AI Shopping Answers Are Becoming Retail's New Shelf

Updated Category News Views 67

Retail’s front door is quietly being moved by a machine, and plenty of big chains appear to be staring at the old entrance. Bain’s latest work lands on an uncomfortable point: owning market share does not guarantee a retailer gets named when an AI assistant answers a shopper’s question. That ought to rattle management teams more than the usual holiday-season...

Continue Reading
Texas Plumbing Award Signals Local Service Discipline

Updated Category News Views 99

A clogged main line is not glamorous, but it is where a local service reputation gets tested for real. Neighborhood Plumbing and Drain has been named a 2026 Best of Texas Award winner in the Plumbing Contractors category, a recognition that matters less as a trophy than as a public signal: customers around Central Texas have noticed the outfit. For anyone watching the...

Continue Reading
TDH's First-Half Revenue Grew, but Margins Vanished

Updated Category News Views 106

A rental business can add tenants and still march backward, and TDH Holdings just demonstrated the ugly math. For the six months ended June 30, 2026, revenue from continuing operations rose 26.45% to $0.74 million. That is the pleasant number, and it deserves exactly one polite nod. Everything beneath it looks far less comfortable: costs climbed faster than revenue, gross...

Continue Reading
Botanica’s Illuminations Carries More Than Holiday Glow

Updated Category News Views 106

Two million lights are doing more than brightening up a few winter evenings in Wichita. Illuminations at Botanica returns from November 23, 2026, through January 2, 2027, and the pleasant part of this story is that the spectacle has a practical backbone: it is Botanica’s largest fundraiser. For a garden nonprofit, that matters a whole lot more than another shiny...

Continue Reading
Cirrus CEO Takes SIA Chair as Chip Policy Heats Up

Updated Category News Views 196

A trade-group gavel rarely moves a stock by itself, but this one lands in a noisy part of the chip cycle. On November 19, 2026, the Semiconductor Industry Association elected Cirrus Logic President and CEO John Forsyth as chair of its board. That is not a revenue announcement, not a factory groundbreaking, and certainly not a reason to start flinging confetti at...

Continue Reading
Illumina's Virtual Cell Win Raises Bigger AI Stakes

Updated Category News Views 97

A blind prediction contest is a useful place to separate glossy AI talk from actual biology. Illumina's BioInsight AI Lab took first place in Arc Institute's 2026 Virtual Cell Challenge, outperforming roughly 1,500 competitors on predictions of how cells would react when genes were knocked down. That is not a quarterly revenue number, and nobody should pretend otherwise....

Continue Reading
COP31 Puts China’s Weather-to-Energy Model on View

Updated Category News Views 55

Storm maps are becoming operating manuals, and that is the hard reality behind a November 13 COP31 event in Antalya, Türkiye. The session, “From Early Warning to Energy Action: Pathways for Global Climate Diplomacy and Cooperation,” put China’s effort to tie meteorological intelligence to energy-system decisions under an international spotlight. This is not...

Continue Reading
AI Governance Is Becoming Enterprise Infrastructure

Updated Category News Views 27

Governance Has Finally Reached the Engine Room Enterprise AI is no longer a shiny pilot parked in some innovation lab; it is creeping into business-critical work, and that changes the argument entirely. Frost & Sullivan’s latest analysis makes a sensible point that too many executives still resist: AI governance is becoming a strategic operating capability, not merely a...

Continue Reading
"btn" href="https://investorshangout.com/blog/news?page=2">More News Articles